Guardant Health Named to TIME’s List of the Best Inventions of 2024
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Business Wire
Shield™, the first FDA-approved, Medicare-reimbursed colorectal cancer screening blood test, named to the Medical Care list PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing lives.To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as health care, AI, and green energy. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.“We’re honored to be a part of this prestigious list of leading innovative products that are making a dramatic difference in how we live our lives today,” said AmirAli Talasaz, co-CEO and co-Founder of Guard
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health, Inc. (NASDAQ: GH) had its price target lowered by analysts at Sanford C. Bernstein from $40.00 to $35.00. They now have an "outperform" rating on the stock.MarketBeat
- Table22 Closes $11M Series A to Power Food and Beverage Merchants' E-Commerce Growth [Yahoo! Finance]Yahoo! Finance
- Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024 [Yahoo! Finance]Yahoo! Finance
- Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024Business Wire
- Roberto A. Mignone Joins Guardant Health Board of Directors [Yahoo! Finance]Yahoo! Finance
GH
Earnings
- 8/7/24 - Beat
GH
Sec Filings
- 10/29/24 - Form 3
- 10/24/24 - Form 8-K
- 10/16/24 - Form 4
- GH's page on the SEC website